| J Drugs Dermatol.
2005 Sep-Oct;4(5):637-40. |
|
Effective treatment of female androgenic alopecia with
dutasteride.
Olszewska M, Rudnicka L.
Department of Dermatology, Warsaw Medical School, Warsaw, Poland.
malgorzataolszewska@yahoo.com
Dihydrotestosterone is the main molecule responsible for androgenic alopecia.
Finasteride, which reduces transformation of testosterone into
dihydrotestosterone and decreases dihydrotestosterone activity, is approved for
treatment of androgenic alopecia in men. We describe the case of a 46-year-old
woman with androgenic alopecia, non-responsive to minoxidil, who initially
benefited from finasteride. Due to only limited improvement after finasteride
and persisting profound psychological distress resulting from androgenic
alopecia, another 5-reductase inhibitor, dutasteride, was introduced. Clinical
evaluation and trichogram were applied for assessment of dutasteride efficacy in
this patient. Additionally, mean hair diameter was monitored by means of
computer dermoscopy. After 6 months of therapy, significant improvement was
observed and after 9 months the clinical diagnosis of androgenic alopecia could
no longer be made in this patient. No side effects were observed. In conclusion,
theoretical data and our experience in this case show that dutasteride might
develop into a true alternative in treatment of androgenic alopecia.
Torna a Avodart ® (marchio registrato) /
Dutasteride
Avodart ® (marchio registrato) (english)